US0887861088
© BusinessWire
16.12.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA) for access to up to 400...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 18, at 10:30 a.m. GMT.
A li...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate updates.
“We are currently seeking broad regula...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
08.09.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Strengthens Board of Directors with New Appointments
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointments of Roger Dansey, M.D., and Hervé Hoppenot to the company’s Board of Directors.
"We are thrilled to welcome Roger and Hervé to...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
02.07.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on July 1, 2025, the Compensation Committee of the company’s Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 77,400 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Induceme...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on June 2, 2025, the Compensation Committee of the company’s Board of Directors granted to seven new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 57,700 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Induceme...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on May 1, 2025, the Compensation Committee of the company’s Board of Directors granted to 13 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 79,500 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducement P...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2025.
“In the first quarter, we continued to advance our bu...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced the presentation of additional human imaging data that validate the potential of MT1-MMP, a tumor antigen overexpressed in many cancers, as a novel...
Themefolio
Profiler
Peergroup
© BusinessWire
02.04.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company’s Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducem...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, at 12:45 p.m....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
27.03.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced several new governance and key clinical leadership appointments.
Felix J. Baker, Ph.D., will succeed Pierre Legault, BAA, MBA, CPA, CA, as chai...
Themefolio
Profiler
Peergroup
© BusinessWire
05.03.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on March 3, 2025, the Compensation Committee of the company’s Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 73,700 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducem...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates.
“In 2024, the significan...
Themefolio
Profiler
Peergroup
© BusinessWire
05.02.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, Feb. 12, at...
Themefolio
Profiler
Peergroup
© BusinessWire
03.02.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on February 3, 2025, the Compensation Committee of the company’s Board of Directors granted to 18 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 117,300 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Induce...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible...
Themefolio
Profiler
Peergroup
© BusinessWire
09.01.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m....
Themefolio
Profiler
Peergroup
© BusinessWire
03.01.2025
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on January 2, 2025, the Compensation Committee of the company’s Board of Directors granted to 12 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 67,300 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Induceme...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 ge...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the compan...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on December 2, 2024, the Compensation Committee of the company’s Board of Directors granted to thirteen new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 62,400 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 I...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cance...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Nov. 19, 2024, at 10:30 a.m. GMT.
A live...
Themefolio
Profiler
Peergroup
© BusinessWire
01.11.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on November 1, 2024, the Compensation Committee of the company’s Board of Directors granted to twelve new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 56,700 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Ind...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the third quarter ended September 30, 2024.
“In the third quarter, we continued to make signi...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of the first human imaging data validating the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrat...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data highlighting its potential to develop differentiated radiopharmaceutical molecules, called Bicycle Radionucli...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on October 1, 2024, the Compensation Committee of the company’s Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 47,600 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Induc...
Themefolio
Profiler
Peergroup
© BusinessWire
14.09.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate (BTC®) zelenectide pevedotin (formerly BT8009) in metastatic urothelial cancer (m...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on September 3, 2024, the Compensation Committee of the company’s Board of Directors granted to seven new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 29,500 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Ind...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2024
BCYC
LISTED
NASDAQ
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in September:
Morgan Stanley 22nd Annual Global Healthcare Conference...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
